The Role of Noncoding RNAs in B-Cell Lymphoma

Abstract

In recent years, emerging evidence has suggested that noncoding RNAs (ncRNAs) participate in nearly every aspect of biological processes and play a crucial role in the genesis and progression of numerous tumors, including B-cell lymphoma. The exploration of ncRNA dysregulations and their functions in B-cell lymphoma provides new insights into lymphoma pathogenesis and is essential for indicating future clinical trials and optimizing the diagnostic and therapeutic strategies. In this review, we summarize the role of ncRNAs in B-cell lymphoma and discuss their potential in clinical applications.

Long Non-Coding RNA Signatures in Lymphopoiesis and Lymphoid Malignancies

“…Several studies have identified differently expressed lncRNAs in B-cell NHLs by using datasets that confirm the findings in tissue samples or cell lines ( Figure 3 ). For example, HAGLROS, MANCR, ROR1-AS1, and MALAT1 were found to be the most important upregulated lncRNAs in MCL patients [ 122 ]. While HAGLROS lead to the progress of MCL through regulation of PI3K/AKT/mTOR signaling [ 123 ], ROR1-AS1 physically interacts with core proteins of the PRC2 complex (especially EZH2) and suppresses the expression of SOX11 [ 124 ].…”

“…As the most common type of NHL, several differentially expressed lncRNAs have been identified in DLBCL. While SNHG14, OR3A4, NEAT1, FIRRE, MALAT1, HOTAIR, LUNAR1, SMAD5-AS1, and HULC are the most important upregulated lncRNAs, PANDA, FAS-AS1, lincRNA-21, and TUG1 are the most studied downregulated lncRNAs in DLBCL [ 122 ]. It has been reported that the lncRNA SNHG14 causes the evasion of malignant cells from the immune system by upregulating the expression of PD-L1 through sponging miR-5590-3p and Zinc finger Ebox binding homeobox 1 (ZEB1) [ 132 ].…”

Non‑coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies (Review)

“…Double-stranded RNAi and ASOs are the most commonly used lncRNA-targeted therapies. When the target lncRNA is localized in the nucleus, ASOs are the better therapeutic option (225).…”

“…The most important finding, by reviewing the literature, is that either the lncRNA expression signature or miRNA expression may help distinguish between the different lymphoma entities. In addition, as certain ncRNAs may be associated with the progression of lymphoma or drug resistance, these ncRNAs can be used as predictive and prognostic markers (225). However, the ncRNA regulatory network is complex and is not yet fully understood, as the majority of ncRNAs have not yet been thoroughly investigated.…”

Targeting the lncRNA DUXAP8/miR-29a/PIK3CA Network Restores Doxorubicin Chemosensitivity via PI3K-AKT-mTOR Signaling and Synergizes With Inotuzumab Ozogamicin in Chemotherapy-Resistant B-Cell Acute Lymphoblastic Leukemia

“…Long non-coding RNA (lncRNA), a kind of non-coding RNA recognized recently with a length of more than 200 bp, has been reported to regulate a huge amount of biological processes and to be involved in the pathogenesis of most diseases via its interaction with cellular compounds such as miRNA, mRNA, DNA, and proteins (9)(10)(11)(12)(13). Besides, lncRNA has been also observed to be deeply involved in the development, progression, and treatment response of hematological malignancies (14)(15)(16). In the aspect of B-ALL, a recent comprehensive bioinformatics analysis identifies 1,235 dysregulated lncRNAs engaged in B-ALL subtype classification, and 942 aberrant lncRNAs related to B-ALL relapse (17).…”